Reneuron Regulatory News (RENE)

ReNeuron Group plc

Guildford, UK, 4 December 2015: ReNeuron Group plc (the "Company") (AIM: RENE), a leading UK-based stem cell therapy development company, is pleased to announce the appointment of Dr Mike Owen as a Non-executive Director of the Company with immediate effect. He will also chair the Company's Scientific Advisory Board.

Dr Owen's career in biotech, the pharmaceutical industry and academia spans almost 40 years. He was formerly Senior Vice President for Biopharmaceuticals Research at GlaxoSmithKline where he was responsible for the discovery and development of antibody drugs in multiple therapeutic areas through to successful clinical proof of concept. He was also a Founder and Chief Scientific Officer of Kymab Ltd, an antibody-based biotech company, and for many years held a research position at the Imperial Cancer Research Fund (now CR-UK).

He currently serves as a director of Zealand Pharma, Ossianix Inc, BliNK Biomedical SAS and Avacta plc and is a member of the Scientific Advisory Boards of Kymab Ltd and the CRT Pioneer Fund LP, and the investor advisory board of HS Lifesciences gmbh. He is a Fellow of the Academy of Medical Sciences and a member of the European Molecular Biology Organisation.

Commenting on Dr Owen's appointment, John Berriman, Chairman of ReNeuron, said:

"I am delighted to welcome Mike to the Board of the Company, and to its Scientific Advisory Board. As a consultant he has already provided much valuable input to the Company's research and development programmes and this, together with his broad experience in progressing cutting edge research projects from the bench to the clinic, makes us confident that this appointment will lead to a significant further strengthening of our Board."

Dr Owen commented:

 "I am delighted to have joined the Board of ReNeuron, and its Scientific Advisory Board, and look forward to helping the Company to realise the potential of its stem cell and related technologies to generate innovative new medicines for diseases of unmet medical need."

Disclosures in accordance with the AIM Rules

Michael John Owen, aged 64, is, or has been a director or partner of the following companies or partnerships during the past five years:

Current Directorships and Partnerships Past Directorships and Partnerships in the previous five years

Avacta plc BliNK Therapeutics Ltd

BliNK Biomedical SAS

Ossianix Inc

The Club Cricket Organisation Ltd

Zealand Pharma A/S

There are no further disclosures required in accordance with AIM Rule 17 and Schedule Two paragraph (g) of the AIM Rules for Companies.

Enquiries:

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.